We then assessed that LRRK2 kinase inhibition reduces the neuroinflammatory response in our in vivo model of AD- and PD-related neuroinflammation by analyzing the proinflammatory mediators IL-1β and iNOS. This evidence concerns the gene LRRK2 and Parkinson disease.